In the course of fertility treatment, it directly affects the lining of the womb to facilitate embryo implantation.
Between September 2021 and January 2023, 96 infertile women under the age of 40 who were undergoing IVF or intracytoplasmic sperm injection (ICSI) using donor eggs at 28 reproductive centers throughout Europe participated in the new study.
Five weeks following the embryo transfer and one menstrual cycle prior, they were given OXO-001 or a placebo. OXO-001 was administered twice daily.
Ten weeks following embryo transfer, researchers examined “ongoing pregnancy rates” and discovered that patients treated with OXO-001 had “ongoing pregnancy rates” of 46.3%, compared to 35.7% for those given a placebo.
Presenting their research at the 40th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Amsterdam, they said that this was a “clinically significant finding.”.
Additionally, they reported a statistically significant rise in the proportion of women who went on to give birth alive.
The study, which is also being published in the journal Human Reproduction, found that the live birth rate was 42.6% for women who took the new pill and 35.7% for those who took a placebo.
